PMC Articles for MedGen (Select 154285) - PMC

Links from MedGen

Items: 1 to 20 of 5568

<< First< Prev

Page of 279

Select item 85728291.

H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology

Serena Ammendola, Nicolò Caldonazzi, Michele Simbolo, Maria Liliana Piredda, Matteo Brunelli, Pietro Luigi Poliani, Giampietro Pinna, Francesco Sala, Claudio Ghimenton, Aldo Scarpa, Valeria Barresi

Virchows Arch. 2021; 479(5): 987–996. Published online 2021 Jun 24. doi: 10.1007/s00428-021-03134-1

PMCID:: PMC8572829

Abstract Article PDF–1.0M

Select item 81342552.

Relatively Decreased ¹¹C-Methionine Uptake within the Anaplastic Component of a Mixed-Grade Oligodendroglioma

K. Miwa, J. Shinoda, H. Yano, T. Iwama

AJNR Am J Neuroradiol. 2007 Nov; 28(10): 2005–2007. doi: 10.3174/ajnr.A0695

PMCID:: PMC8134255

Abstract Article PDF–494K

Select item 67390713.

Correction to: Phase I–II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG)

Kurt A. Jaeckle, S. K. Anderson, Erin L. Twohy, Jesse G. Dixon, Caterina Giannini, Robert Jenkins, Merrill J. Egorin, Jann N. Sarkaria, Paul D. Brown, P. J. Flynn, John Schwerkoske, Jan C. Buckner, Evanthia Galanis

J Neurooncol. Author manuscript; available in PMC 2020 Jul 1.

Published in final edited form as: J Neurooncol. 2019 Jul; 143(3): 583. doi: 10.1007/s11060-019-03201-3

Corrects:: J Neurooncol. 2019 Jul; 143(3): 573–581.

PMCID:: PMC6739071

Correction PDF–27K

Select item 67176514.

PHASE I-II TRIAL OF IMATINIB MESYLATE (GLEEVEC; STI571) IN TREATMENT OF RECURRENT OLIGODENDROGLIOMA AND MIXED OLIGOASTROCYTOMA. NORTH CENTRAL CANCER TREATMENT GROUP STUDY N0272 (ALLIANCE/NCCTG)

Kurt A. Jaeckle, S K. Anderson, Erin L. Twohy, Jesse G. Dixon, Caterina Giannini, Robert Jenkins, Merrill J. Egorin, Jann N. Sarkaria, Paul D. Brown, P J. Flynn, John Schwerkoske, Jan C. Buckner, Eva Galanis

J Neurooncol. Author manuscript; available in PMC 2020 Jul 1.

Published in final edited form as: J Neurooncol. 2019 Jul; 143(3): 573–581. Published online 2019 May 22. doi: 10.1007/s11060-019-03194-z

Correction in:: J Neurooncol. 2019 Jul; 143(3): 583.

PMCID:: PMC6717651

Abstract Article PDF–215K

Select item 57842265.

Reclassification of Mixed Oligoastrocytic Tumors Using a Genetically Integrated Diagnostic Approach

Seong-Ik Kim, Yujin Lee, Jae-Kyung Won, Chul-Kee Park, Seung Hong Choi, Sung-Hye Park

J Pathol Transl Med. 2018 Jan; 52(1): 28–36. Published online 2017 Sep 29. doi: 10.4132/jptm.2017.09.25

PMCID:: PMC5784226

Abstract Article PDF–4.0M

Select item 45841766.

Phase II Trial of Pre-Irradiation and Concurrent Temozolomide in Patients with Newly Diagnosed Anaplastic Oligodendrogliomas and Mixed Anaplastic Oligoastrocytomas: Long Term Results of RTOG BR0131

Michael A. Vogelbaum, Chen Hu, David M. Peereboom, David R. Macdonald, Caterina Giannini, John H. Suh, Robert B. Jenkins, Nadia N. Laack, David G. Brachman, Dennis C. Shrieve, Luis Souhami, Minesh P. Mehta

J Neurooncol. Author manuscript; available in PMC 2016 Sep 1.

Published in final edited form as: J Neurooncol. 2015 Sep; 124(3): 413–420. Published online 2015 Jun 19. doi: 10.1007/s11060-015-1845-7

PMCID:: PMC4584176

Abstract Article PDF–528K

Select item 42266687.

Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas

Jane B. Cryan, Sam Haidar, Lori A. Ramkissoon, Wenya Linda Bi, David S. Knoff, Nikolaus Schultz, Malak Abedalthagafi, Loreal Brown, Patrick Y. Wen, David A. Reardon, Ian F. Dunn, Rebecca D. Folkerth, Sandro Santagata, Neal I. Lindeman, Azra H. Ligon, Rameen Beroukhim, Jason L. Hornick, Brian M. Alexander, Keith L. Ligon, Shakti H. Ramkissoon

Oncotarget. 2014 Sep; 5(18): 8083–8092. Published online 2014 Aug 12. doi: 10.18632/oncotarget.2342

PMCID:: PMC4226668

Abstract Article PDF–1.1M

Select item 38708298.

Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas

Andrew L. Lin, Jingxia Liu, John Evans, Eric C. Leuthardt, Keith M. Rich, Ralph G. Dacey, Joshua L. Dowling, Albert H. Kim, Gregory J. Zipfel, Robert L. Grubb, Jiayi Huang, Clifford G. Robinson, Joseph R. Simpson, Gerald P. Linette, Michael R. Chicoine, David D. Tran

Neuro Oncol. 2014 Jan; 16(1): 123–130. Published online 2013 Nov 26. doi: 10.1093/neuonc/not142

PMCID:: PMC3870829

Abstract Article PDF–189K

Select item 36788839.

A “Weighted” Fluorescence In Situ Hybridization Strengthens the Favorable Prognostic Value of 1p/19q Codeletion in Pure and Mixed Oligodendroglial Tumors

Rebecca Senetta, Ludovica Verdun di Cantogno, Luigi Chiusa, Isabella Castellano, Patrizia Gugliotta, Anna Sapino, Paola Cassoni

J Neuropathol Exp Neurol. 2013 May; 72(5): 432–441. Published online 2013 Apr 26. doi: 10.1097/NEN.0b013e3182901f41

PMCID:: PMC3678883

Abstract Article PDF–3.6M

Select item 287893410.

Cognition and Quality of Life after Chemotherapy plus Radiotherapy (RT) vs. RT for Pure and Mixed Anaplastic Oligodendrogliomas: Radiation Therapy Oncology Group Trial 9402

Meihua Wang, Gregory Cairncross, Edward Shaw, Robert Jenkins, Bernd Scheithauer, David Brachman, Jan Buckner, Karen Fink, Luis Souhami, Normand Laperriere, Minesh Mehta, Walter Curran

Int J Radiat Oncol Biol Phys. Author manuscript; available in PMC 2011 Jul 1.

Published in final edited form as: Int J Radiat Oncol Biol Phys. 2010 Jul 1; 77(3): 662–669. Published online 2009 Sep 23. doi: 10.1016/j.ijrobp.2009.06.004

PMCID:: PMC2878934

Abstract Article PDF–642K

Select item 271898811.

Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131

Michael A. Vogelbaum, Brian Berkey, David Peereboom, David Macdonald, Caterina Giannini, John H. Suh, Robert Jenkins, James Herman, Paul Brown, Deborah T. Blumenthal, Christopher Biggs, Christopher Schultz, Minesh Mehta

Neuro Oncol. 2009 Apr; 11(2): 167–175. doi: 10.1215/15228517-2008-073

PMCID:: PMC2718988

Abstract Article PDF–296K

Select item 1111255912.

Research on Gas Multi-indicator Warning Method of Coal Mine Working Face Based on MOA-Transformer

Huan Yang, Jian Wang, Haoliang Zhang

ACS Omega. 2024 May 21; 9(20): 22136–22144. Published online 2024 May 7. doi: 10.1021/acsomega.4c00519

PMCID:: PMC11112559

Abstract Article PDF–3.0M

Select item 1083227313.

Mediators of the effects of exercise and manual therapy for people with knee and hip osteoarthritis: A secondary, exploratory analysis of the MOA trial

Daniel Cury Ribeiro, Sarah E. Lamb, J. Haxby Abbott

Osteoarthr Cartil Open. 2024 Mar; 6(1): 100431. Published online 2024 Jan 9. doi: 10.1016/j.ocarto.2023.100431

PMCID:: PMC10832273

Abstract Article PDF–506K

Select item 1070259214.

The creative behavior of virtual idol fans: a psychological perspective based on MOA theory

Qingnian Wang, Shuyu Long, Yanfei Zeng, Lan Tang, Yunpei Wang

Front Psychol. 2023; 14: 1290790. Published online 2023 Nov 21. doi: 10.3389/fpsyg.2023.1290790

PMCID:: PMC10702592

Abstract Article PDF–1.0M

Select item 1063785615.

Open MoA: revealing the mechanism of action (MoA) based on network topology and hierarchy

Xinmeng Liao, Mehmet Ozcan, Mengnan Shi, Woonghee Kim, Han Jin, Xiangyu Li, Hasan Turkez, Adnane Achour, Mathias Uhlén, Adil Mardinoglu, Cheng Zhang

Bioinformatics. 2023 Nov; 39(11): btad666. Published online 2023 Oct 31. doi: 10.1093/bioinformatics/btad666

PMCID:: PMC10637856

Abstract Article PDF–4.6M

Select item 1010449716.

High-resolution structural information of membrane-bound α-synuclein provides insight into the MoA of the anti-Parkinson drug UCB0599

Thomas C. Schwarz, Andreas Beier, Karin Ledolter, Thomas Gossenreiter, Theresa Höfurthner, Markus Hartl, Terry S. Baker, Richard J. Taylor, Robert Konrat

Proc Natl Acad Sci U S A. 2023 Apr 11; 120(15): e2201910120. Published online 2023 Apr 7. doi: 10.1073/pnas.2201910120